Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TK1 | P04183 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.46 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780047 | 0.92 | TK1 (0.49) | TK1BCHETYMP | |
| SCHEMBL780058 | 0.91 | TYMP (0.44) | TYMP | |
| SCHEMBL25414279 | 0.90 | TYMS (0.44) | TK1TYMP | |
| SCHEMBL780214 | 0.89 | TYMP (0.43) | TYMP | |
| SCHEMBL3568613 | 0.88 | DUT (0.53) | TYMP | |
| SCHEMBL10446716 | 0.85 | POLB (0.58) | POLBTK1BCHETYMP | |
| SCHEMBL1727537 | 0.85 | POLB (0.58) | POLBTK1BCHETYMP | |
| SCHEMBL1727320 | 0.85 | POLB (0.58) | POLBTK1BCHETYMP | |
| SCHEMBL6334503 | 0.85 | POLB (0.58) | POLBTK1BCHETYMP | |
| SCHEMBL6077816 | 0.85 | POLB (0.58) | POLBTK1BCHETYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8298414-B2 | Separation process | GE HEALTHCARE LIMITED (GB) | 2012-10-30 | — | — | US | claimed |
| US-20120138520-A1 | SEPARATION PROCESS | GE HEALTHCARE LIMITED (GB) | 2012-06-07 | — | — | US | claimed |
| US-11094424-B2 | Closed evaporation system | GE HEALTHCARE LIMITED (GB) | 2021-08-17 | — | — | US | disclosed |
| EP-3058575-B1 | CLOSED EVAPORATION SYSTEM | GE HEALTHCARE UK LTD (GB) | 2020-04-15 | — | — | EP | disclosed |
| US-20200043620-A1 | CLOSED EVAPORATION SYSTEM | GE HEALTHCARE LTD (GB) | 2020-02-06 | — | — | US | disclosed |
| CN-105612583-B | Closed evaporation system | 通用电气健康护理有限公司 | 2018-05-29 | — | — | CN | disclosed |
| US-20160260511-A1 | CLOSED EVAPORATION SYSTEM | GE HEALTHCARE LIMITED (GB) | 2016-09-08 | — | — | US | disclosed |
| EP-3058575-A1 | CLOSED EVAPORATION SYSTEM | GE Healthcare UK Limited (GB) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015055806-A1 | CLOSED EVAPORATION SYSTEM | GE HEALTHCARE LIMITED (GB) | 2015-04-23 | — | — | WO | disclosed |
| US-8298414-B2 | Separation process | GE HEALTHCARE LIMITED (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20120138520-A1 | SEPARATION PROCESS | GE HEALTHCARE LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-8137560-B2 | Separation process | GE HEALTHCARE LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| WO-2010108135-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2010-09-23 | — | — | WO | disclosed |
| US-20100105888-A1 | SEPARATION PROCESS | GE HEALTHCARE LIMITED (GB) | 2010-04-29 | — | — | US | disclosed |
| EP-2121542-A1 | SEPARATION PROCESS | GE Healthcare Limited (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008110757-A1 | SEPARATION PROCESS | GE HEALTHCARE LIMITED (GB) | 2008-09-18 | — | — | WO | disclosed |
| US-6891033-B2 | Chemical intermediates such as 3-N-Boc-1-(5-O-(4,4'-dimethoxytrityl)-3-O-nosyl-2-deoxy-beta-D -lyxofuranosyl)thymine; use of final compound in positron emission tomography (PET) | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2005-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200043620-A1 | CLOSED EVAPORATION SYSTEM | RNF168, EXOSC5, SLC43A1 | POLB 201/4885TK1 727/4885BCHE 729/4885 |
| US-20100105888-A1 | SEPARATION PROCESS | PAICS, EPHX2, SAMHD1 | POLB 745/4885TK1 337/4885BCHE 63/4885 |
| US-20100240604-A1 | PROTECTED NUCLEOTIDE ANALOGS | PNP, NTPCR, TYMP | POLB 89/4885TK1 51/4885BCHE 3587/4885 |
| US-11094424-B2 | Closed evaporation system | RNF168, EXOSC5, SLC43A1 | POLB 201/4885TK1 727/4885BCHE 729/4885 |
| US-20160260511-A1 | CLOSED EVAPORATION SYSTEM | RNF168, EXOSC5, SLC43A1 | POLB 201/4885TK1 727/4885BCHE 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.